422 related articles for article (PubMed ID: 16982322)
1. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R; Hieronimus N; Steidl U; Bruns I; Graef T; Zohren F; Ruf L; Haas R; Kobbe G
Exp Hematol; 2006 Oct; 34(10):1296-302. PubMed ID: 16982322
[TBL] [Abstract][Full Text] [Related]
2. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
Milano-Bausset E; Gaudart J; Rome A; Coze C; Gentet JC; Padovani L; Lacarelle B; André N
Clin Ther; 2009; 31 Pt 2():2388-95. PubMed ID: 20110048
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
Staber PB; Holub R; Linkesch W; Schmidt H; Neumeister P
Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
[TBL] [Abstract][Full Text] [Related]
7. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
Samaras P; Blickenstorfer M; Siciliano RD; Haile SR; Buset EM; Petrausch U; Mischo A; Honegger H; Schanz U; Stussi G; Stahel RA; Knuth A; Stenner-Liewen F; Renner C
Ann Hematol; 2011 Jan; 90(1):89-94. PubMed ID: 20706722
[TBL] [Abstract][Full Text] [Related]
8. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
Vanstraelen G; Frère P; Ngirabacu MC; Willems E; Fillet G; Beguin Y
Exp Hematol; 2006 Mar; 34(3):382-8. PubMed ID: 16543072
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
11. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Steidl U; Fenk R; Bruns I; Neumann F; Kondakci M; Hoyer B; Gräf T; Rohr UP; Bork S; Kronenwett R; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jan; 35(1):33-6. PubMed ID: 15531906
[TBL] [Abstract][Full Text] [Related]
12. Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques.
Farese AM; Yang BB; Roskos L; Stead RB; MacVittie TJ
Bone Marrow Transplant; 2003 Aug; 32(4):399-404. PubMed ID: 12900776
[TBL] [Abstract][Full Text] [Related]
13. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
14. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation.
Shimazaki C; Uchiyama H; Fujita N; Araki S; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Haruyama H
Exp Hematol; 1995 Dec; 23(14):1497-502. PubMed ID: 8542937
[TBL] [Abstract][Full Text] [Related]
16. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.
Hosing C; Qazilbash MH; Kebriaei P; Giralt S; Davis MS; Popat U; Anderlini P; Shpall EJ; McMannis J; Körbling M; Champlin RE
Br J Haematol; 2006 Jun; 133(5):533-7. PubMed ID: 16681642
[TBL] [Abstract][Full Text] [Related]
17. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
Kroschinsky F; Hölig K; Ehninger G
Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Viola A; Delia R; Carbone A; Celentano M
Hematol Oncol; 2011 Sep; 29(3):139-43. PubMed ID: 21922508
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
